Cogent Biosciences, Inc. (COGT)
| Market Cap | 350.67M |
| Revenue (ttm) | 312,000 |
| Net Income (ttm) | -194.00M |
| Shares Out | 39.85M |
| EPS (ttm) | -7.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 159,418 |
| Open | 8.70 |
| Previous Close | 8.99 |
| Day's Range | 8.32 - 9.01 |
| 52-Week Range | 2.20 - 14.44 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 19.83 (+125.3%) |
| Est. Earnings Date | Nov 9, 2021 |
About COGT
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and ...
Financial Performance
In 2020, COGT's revenue was $7.87 million, a decrease of -65.02% compared to the previous year's $22.50 million. Losses were -$179.21 million, 463.0% more than in 2019.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for COGT stock is "Strong Buy." The 12-month stock price forecast is 19.83, which is an increase of 125.34% from the latest price.
News
Cogent Biosciences Provides Corporate Updates and Reports Second Quarter 2021 Financial Results
CAMBRIDGE, Mass. and BOULDER, Colo.
Cogent Biosciences to Present at Wedbush PacGrow Virtual Healthcare Conference 2021
CAMBRIDGE, Mass. and BOULDER, Colo.
Cogent Biosciences to Present at Ladenburg Thalmann Virtual Healthcare Conference 2021
CAMBRIDGE, Mass. and BOULDER, Colo.
Cogent Biosciences to Present at Jefferies Virtual Healthcare Conference 2021
CAMBRIDGE, Mass. and BOULDER, Colo.
Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results
CAMBRIDGE, Mass. and BOULDER, Colo.
Cogent Biosciences Appoints Evan Kearns as Chief Legal Officer
CAMBRIDGE, Mass. and BOULDER, Colo.
Cogent Biosciences Announces Creation of Cogent Research Team
BOULDER, Colo. and CAMBRIDGE, Mass.
Cogent Biosciences, Inc. (COGT) Reports Q4 Loss, Lags Revenue Estimates
Cogent Biosciences, Inc. (COGT) delivered earnings and revenue surprises of -1910.00% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for th...
Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results
CAMBRIDGE, Mass., March 16, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announ...
Cogent Biosciences Appoints Accomplished Finance Executive Todd E. Shegog to its Board of Directors
CAMBRIDGE, Mass., Feb. 22, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...
Cogent Biosciences to Present at Virtual 10th Annual SVB Leerlink Global Healthcare Conference 2021
CAMBRIDGE, Mass., Feb. 18, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...
Cogent Biosciences to Present at LifeSci Partners Virtual Precision Oncology Day 2021
CAMBRIDGE, Mass., Feb. 11, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriter's Op...
CAMBRIDGE, Mass., Dec. 4, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. ("Cogent") (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, tod...
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
CAMBRIDGE, Mass., Dec. 1, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announce...
Cogent Biosciences Announces $60.0 Million Public Offering of Shares of Common Stock
CAMBRIDGE, Mass., Nov. 30, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...
Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual Conference
CAMBRIDGE, Mass., Nov. 20, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...
Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare Conference
CAMBRIDGE, Mass., Nov. 12, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...
Cogent Biosciences Appoints Andrew Robbins as Chief Executive Officer
CAMBRIDGE, Mass., Oct. 26, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. ("Cogent") (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, to...
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational P...
CAMBRIDGE, Mass., Oct. 5, 2020 /PRNewswire/ -- Unum Therapeutics Inc. ("Unum") (NASDAQ: UMRX), a biotechnology company focused on developing precision therapies for genetically defined diseases, today a...
Is Unum Therapeutics (UMRX) Stock Outpacing Its Medical Peers This Year?
Is (UMRX) Outperforming Other Medical Stocks This Year?
Unum Therapeutics Transfers BOXR Cell-Based Therapy Technology to SOTIO
CAMBRIDGE, Mass., Aug. 31, 2020 /PRNewswire/ -- Unum Therapeutics Inc.
Unum Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
CAMBRIDGE, Mass., Aug. 11, 2020 /PRNewswire/ -- Unum Therapeutics Inc.
Nasdaq Tops 11,000: 5 Best Stocks With Room for More Upside
On Aug 6, the Nasdaq Composite Index topped the milestone of 11,000. The tech-heavy laden completed its 1000-point journey in 40 trading days, representing the fastest ever rise in 20 years.
Is Unum Therapeutics (UMRX) Outperforming Other Medical Stocks This Year?
Is (UMRX) Outperforming Other Medical Stocks This Year?
Unum Therapeutics Inc. (UMRX) Outpaces Stock Market Gains: What You Should Know
Unum Therapeutics Inc. (UMRX) closed the most recent trading day at $2.74, moving +1.86% from the previous trading session.